3 terminated, 1 active not recruiting, 1 completed, 1 recruiting. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Anthos Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) Abelacimab, Placebo - Atrial Fibrillation (AF) | Phase 3 | Recruiting | Anthos Therapeutics, Inc. | 2500 | 2022-12-27 | 2026-07-13 |
| A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Abelacimab, Dalteparin - Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Terminated | Anthos Therapeutics, Inc. | 417 | 2022-09-27 | 2026-04-17 |
| Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke Atrial Fibrillation | Terminated | Anthos Therapeutics, Inc. | 705 | 2022-09-14 | 2024-12-03 | |
| A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE Abelacimab, Apixaban - Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Terminated | Anthos Therapeutics, Inc. | 1150 | 2022-05-05 | 2026-02-23 |
| Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation Abelacimab, Rivaroxaban - Atrial Fibrillation (AF), Stroke | Phase 2 | Active not recruiting | Anthos Therapeutics, Inc. | 1287 | 2021-02-02 | 2025-11-06 |
| A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation MAA868 Cohort 1, MAA868 Cohort 2, MAA868 Cohort 3 - Atrial Fibrillation | Phase 2 | Completed | Anthos Therapeutics, Inc. | 28 | 2019-12-11 | 2022-01-11 |
Atrial Fibrillation (4) · Stroke (3) · Pulmonary Embolism (2) · Venous Thromboembolism (2) · Venous Thrombosis (2) · Arrhythmias, Cardiac (1) · Gastrointestinal Neoplasms (1) · Hemorrhage (1)
MAA868 (4) · abelacimab (4) · Dalteparin (1) · Rivaroxaban (1) · apixaban (1)
United States (6) · Canada (5) · Czechia (5) · Hungary (5) · Germany (4) · Italy (4) · South Korea (4) · Spain (4) · United Kingdom (4) · China (3) · Latvia (3) · Poland (3) · Sweden (3) · Taiwan (3) · Argentina (2)
Norman E Lepor, MD FACC FAHA FSCAI (1)
PMID 39094433, PMID 39842011, PMID 40546068, PMID 41637102, PMID 42213637
2023 (2)